Assessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1
Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1
The 7K SomaScan Assay v4.1 is capable of measuring 7,288 human proteins. In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates.(1) Included in the study design were inter-plate technical duplicates from 102 human subjects, which allowed them to characterize different normalization procedures, evaluate assay variability by multiple analytical approaches, present signal-over-background metrics, and discuss potential specificity issues.
By providing detailed performance assessments on this wide range of technical aspects, the presenters aim for this work to serve as a valuable resource for the growing community of SomaScan users.
Topics covered:
- A comparative analysis of different normalization strategies
- An analysis of performance across 7,288 SOMAmers® Reagents targeting human proteins
- A discussion of sensitivity and specificity of the assay
Julián Candia, PhD
Staff Scientist
Longitudinal Studies Section
Translational Gerontology Branch
National Institute on Aging
National Institutes of Health
Keenan Walker, PhD
Investigator, National Institute on Aging Intramural Research Program
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND) unit
Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1
A presentation by Julián Candia, PhD, and Keenan Walker, PhD
References
- Candia J, Daya GN, Tanaka T, Ferrucci L, Walker KA. Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci Rep. 2022 Oct 13;12(1):17147. doi: 10.1038/s41598-022-22116-0. PMID: 36229504; PMCID: PMC9561184.
More webinars
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.
WebinarData Summit 2025
Take your research further with expert insights from the SomaScan™ Data Summit. Explore the latest platform updates, advanced data analysis tools, and innovative applications for SOMAmer™ reagents. From optimizing sample quality to customizing panels beyond 7K and 11K, this event is packed with knowledge to help you get the most from your data.